9 research outputs found
The genesis of the cellular precipitation reaction
The morphology of cellular precipitation in a Cu-9.5 at. pet In alloy has been investigated by light and electron microscopy. Both cellular and general precipitation were observed to occur simultaneously in quenched and aged alloys while only cellular precipitation was observed to occur in isothermally aged alloys. Because of the presence of wide, solute rich, precipitate free zones in the vicinity of grain boundaries in the quenched and aged alloys, the early development of cellular precipitation was found to be identical for both types of heat treatment. From light and electron microscopy observations of the early stages of cellular precipitation a mechanism for the formation of cells was developed. At the start of aging, the unoccupied grain boundary begins to migrate under the influence of grain boundary migration forces as if it were in a single phase alloy. As the boundary migrates, solute segregates along it to form allotriomorphs which pin the boundary. The boundary continues to migrate and bows between the simultaneously forming allotriomorphs. With further aging, the allotriomorphs lengthen following the bowing boundary and the allotriomorphs become the initial precipitate lamellae of the developing cell as a steady-state lamellar structure develops. Assuming that the critical step in the development of a cell is the ability of the boundary to bow between the initial allotriomorphs, a criterion for the occurrence of cellular precipitation was developed. © 1972 The Metallurgical of Society of AIME
The Potential of Neutron Capture Therapy in the Management of Uncontrollable Localised Tumours
Medicines and the media: news reports of medicines recommended for government reimbursement in Australia
Colorectal Endoscopic Stenting Trial (CReST) for obstructing left-sided colorectal cancer: randomized clinical trial
Background
Colorectal cancer often presents with obstruction needing urgent, potentially life-saving decompression. The comparative efficacy and safety of endoluminal stenting versus emergency surgery as initial treatment for such patients is uncertain.
Methods
Patients with left-sided colonic obstruction and radiological features of carcinoma were randomized to endoluminal stenting using a combined endoscopic/fluoroscopic technique followed by elective surgery 1–4 weeks later, or surgical decompression with or without tumour resection. Treatment allocation was via a central randomization service using a minimization procedure stratified by curative intent, primary tumour site, and severity score (Acute Physiology And Chronic Health Evaluation). Co-primary outcome measures were duration of hospital stay and 30-day mortality. Secondary outcomes were stoma formation, stenting completion and complication rates, perioperative morbidity, 6-month survival, 3-year recurrence, resource use, adherence to chemotherapy, and quality of life. Analyses were undertaken by intention to treat.
Results
Between 23 April 2009 and 22 December 2014, 245 patients from 39 hospitals were randomized. Stenting was attempted in 119 of 123 allocated patients (96.7 per cent), achieving relief of obstruction in 98 of 119 (82.4 per cent). For the 89 per cent treated with curative intent, there were no significant differences in 30-day postoperative mortality (3.6 per cent (4 of 110) versus 5.6 per cent (6 of 107); P = 0.48), or duration of hospital stay (median 19 (i.q.r. 11–34) versus 18 (10–28) days; P = 0.94) between stenting followed by delayed elective surgery and emergency surgery. Among patients undergoing potentially curative treatment, stoma formation occurred less frequently in those allocated to stenting than those allocated to immediate surgery (47 of 99 (47.5 per cent) versus 72 of 106 (67.9 per cent); P = 0.003). There were no significant differences in perioperative morbidity, critical care use, quality of life, 3-year recurrence or mortality between treatment groups.
Conclusion
Stenting as a bridge to surgery reduces stoma formation without detrimental effects. Registration number: ISRCTN13846816 (http://www.controlled-trials.com)